AI Engines For more Details: Perplexity Kagi Labs You
Research Tool: Gabazine bromide is primarily used as a pharmacological tool in scientific research to study the function of GABAA receptors and the role of inhibitory neurotransmission in the central nervous system. By blocking specific subtypes of GABAA receptors, gabazine bromide helps researchers investigate the physiological and pharmacological properties of these receptors and their implications for various neurological and psychiatric conditions.
Seizure Research: Since GABAA receptors mediate inhibitory neurotransmission and play a role in the regulation of neuronal excitability, gabazine bromide is often used in experimental models of epilepsy and seizure disorders. By blocking GABAA receptors, gabazine bromide can induce seizure-like activity in animal models, allowing researchers to study the mechanisms underlying seizures and explore potential antiepileptic drugs.
Neurological Disorders: While gabazine bromide itself is not used clinically to treat neurological disorders, research involving this compound has contributed to our understanding of the pathophysiology of conditions such as epilepsy, anxiety disorders, and neuropathic pain. Insights gained from studies using gabazine bromide may inform the development of novel therapeutic strategies targeting GABAA receptors for the management of these disorders.
Pharmacological Studies: Gabazine bromide is also used in pharmacological studies to investigate the effects of GABAA receptor antagonism on behavior, cognition, and neurotransmitter systems. By modulating GABAA receptor activity, gabazine bromide can alter synaptic transmission and neuronal excitability, leading to changes in animal behavior and cognitive function. These studies help elucidate the role of GABAA receptors in normal brain function and their involvement in neuropsychiatric conditions.
Drug Development: Insights gained from research involving gabazine bromide may have implications for the development of new therapeutic agents targeting GABAA receptors. By identifying specific receptor subtypes involved in various neurological disorders, researchers can design more selective drugs with improved efficacy and fewer side effects compared to non-selective GABAA receptor antagonists like gabazine bromide.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.4 | -0.4 | |
| ADHD | 3.3 | 0.2 | 15.5 |
| Age-Related Macular Degeneration and Glaucoma | 0.7 | 0 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.6 | 1.9 | -2.17 |
| Allergies | 3.8 | 1.6 | 1.37 |
| Allergy to milk products | 0.6 | 0.5 | 0.2 |
| Alopecia (Hair Loss) | 1.1 | 1.1 | |
| Alzheimer's disease | 1.7 | 4 | -1.35 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.6 | 1.83 |
| Ankylosing spondylitis | 2.1 | 0.8 | 1.63 |
| Anorexia Nervosa | 0 | 1.5 | 0 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 0.9 | 1 | -0.11 |
| Atherosclerosis | 1 | 1 | 0 |
| Atrial fibrillation | 2.1 | 0.6 | 2.5 |
| Autism | 5.5 | 5.1 | 0.08 |
| Barrett esophagus cancer | 0.3 | 0.1 | 2 |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.4 | 1.1 | -1.75 |
| Brain Trauma | 0.8 | 0.6 | 0.33 |
| Carcinoma | 2.5 | 2 | 0.25 |
| Celiac Disease | 0.9 | 2.9 | -2.22 |
| Cerebral Palsy | 1 | 1.2 | -0.2 |
| Chronic Fatigue Syndrome | 3.1 | 2.9 | 0.07 |
| Chronic Kidney Disease | 1.6 | 1.2 | 0.33 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.6 | 0.5 |
| Chronic Urticaria (Hives) | 0.7 | 0.4 | 0.75 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 1.1 | -1.75 |
| Colorectal Cancer | 1.9 | 0.9 | 1.11 |
| Constipation | 0.4 | 0.8 | -1 |
| Coronary artery disease | 1 | 0.7 | 0.43 |
| COVID-19 | 7.5 | 7.8 | -0.04 |
| Crohn's Disease | 3.8 | 3.3 | 0.15 |
| cystic fibrosis | 0.2 | 1 | -4 |
| deep vein thrombosis | 0.2 | 0.7 | -2.5 |
| Depression | 5.6 | 5 | 0.12 |
| Dermatomyositis | 0.1 | 0.4 | -3 |
| Eczema | 0.7 | 0.9 | -0.29 |
| Endometriosis | 1.6 | 0.8 | 1 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.8 | 1.4 | 0.29 |
| Fibromyalgia | 1.4 | 0.6 | 1.33 |
| Functional constipation / chronic idiopathic constipation | 2.4 | 2.1 | 0.14 |
| gallstone disease (gsd) | 1.3 | 0.8 | 0.63 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.9 | -2 |
| Generalized anxiety disorder | 0.9 | 1.3 | -0.44 |
| giant cell arteritis | 0.1 | -0.1 | |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 1 | 1.5 | -0.5 |
| Halitosis | 0.5 | 0.1 | 4 |
| Hashimoto's thyroiditis | 2.5 | 0.6 | 3.17 |
| Hidradenitis Suppurativa | 0.1 | 0.3 | -2 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.6 | 0.7 | 2.71 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | 0 |
| hyperglycemia | 0.1 | 1.4 | -13 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.4 | 1.5 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 1.5 | 3.9 | -1.6 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 1.6 | -1.6 | |
| Inflammatory Bowel Disease | 2.5 | 4.5 | -0.8 |
| Insomnia | 0.7 | 0.8 | -0.14 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.7 | 0.4 | 0.75 |
| Irritable Bowel Syndrome | 2.4 | 2.2 | 0.09 |
| Liver Cirrhosis | 2.7 | 2.1 | 0.29 |
| Long COVID | 3.8 | 6.6 | -0.74 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 0.3 | 1.1 | -2.67 |
| ME/CFS with IBS | 0.4 | 1.8 | -3.5 |
| ME/CFS without IBS | 1.4 | 1.4 | 0 |
| Menopause | 2 | 2 | |
| Metabolic Syndrome | 4.8 | 5.4 | -0.13 |
| Mood Disorders | 7.3 | 5.3 | 0.38 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.4 | 1 |
| Multiple Sclerosis | 3.7 | 1.7 | 1.18 |
| Multiple system atrophy (MSA) | 1.6 | 0.9 | 0.78 |
| Neuropathy (all types) | 0.6 | 0.1 | 5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 4.3 | -2.07 |
| NonCeliac Gluten Sensitivity | 0.4 | -0.4 | |
| Obesity | 6.6 | 2.8 | 1.36 |
| obsessive-compulsive disorder | 3.1 | 2.8 | 0.11 |
| Osteoarthritis | 1 | 0.2 | 4 |
| Osteoporosis | 1 | 0.8 | 0.25 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 1.8 | 1.8 | 0 |
| Polycystic ovary syndrome | 0.9 | 1.6 | -0.78 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.4 | -3 |
| Premenstrual dysphoric disorder | 1.2 | 0 | 0 |
| primary biliary cholangitis | 0.3 | 0.4 | -0.33 |
| Psoriasis | 3.2 | 0.9 | 2.56 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.2 | 2.3 | 0.83 |
| Rosacea | 1.3 | 0.5 | 1.6 |
| Schizophrenia | 4.4 | 1.4 | 2.14 |
| scoliosis | 0.5 | -0.5 | |
| Sjögren syndrome | 1.6 | 2.2 | -0.38 |
| Sleep Apnea | 0.9 | 1.2 | -0.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.7 | -1.33 |
| Stress / posttraumatic stress disorder | 1.6 | 2.2 | -0.38 |
| Systemic Lupus Erythematosus | 1.8 | 1.7 | 0.06 |
| Tic Disorder | 0.4 | 1.1 | -1.75 |
| Tourette syndrome | 0.1 | 0.2 | -1 |
| Type 1 Diabetes | 1.6 | 1.6 | 0 |
| Type 2 Diabetes | 4.7 | 3 | 0.57 |
| Ulcerative colitis | 1.7 | 2.1 | -0.24 |
| Unhealthy Ageing | 2.7 | 1.4 | 0.93 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.